FDA Approval Insights: Adjuvant Pembrolizumab in RCC
Season 6, Episode 15, Dec 06, 2021, 08:50 PM
Dr. Choueiri discusses the significance of the FDA approval of pembrolizumab as adjuvant therapy in renal cell carcinoma and key data from the pivotal phase 3 KEYNOTE-564 trial.